Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01006876 · ClinicalTrials.gov registry record · Phase 3
Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation
A Phase 3 study, sponsored by Texas Cardiac Arrhythmia Research Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,584
- Enrollment target
NCT01006876 is a Phase 3 study that has completed, run by Texas Cardiac Arrhythmia Research Foundation. The registered enrollment target is 1,584 participants.
The verdict
NCT01006876, a Phase 3 study, has completed, sponsored by Texas Cardiac Arrhythmia Research Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,584 participants
- Enrollment target
Study Summary
This study aims to explore the risk of periprocedural thromboembolic events in continuous versus interrupted Coumadin therapy in a large, randomized high-risk patient population undergoing radio-frequency catheter ablation for atrial fibrillation.
Interventions
- DRUG Coumadin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,584 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01006876
The ClinicalTrials.gov registry entry for NCT01006876 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,584 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Cardiac Arrhythmia Research Foundation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Coumadin is the first listed.
NCT01006876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01006876 about?
NCT01006876 is a clinical study titled "Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation". This study aims to explore the risk of periprocedural thromboembolic events in continuous versus interrupted Coumadin therapy in a large, randomized high-risk patient population undergoing radio-frequency catheter ablation for atrial fibrillation.
What is the current status of trial NCT01006876?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,584 participants. The study started on 2010-01. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01006876?
The interventions under investigation include: Coumadin (DRUG).
Who is sponsoring clinical trial NCT01006876?
This trial is sponsored by Texas Cardiac Arrhythmia Research Foundation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.